Microenvironmental Regulation of Ovarian Cancer Metastasis

Cancer Treatment and Research

Volumn 149, Issue , 2009, Pages 319-335

  Barbolina, Maria V ^a   Moss, Natalie M ^b   Westfall, Suzanne D ^c   Liu, Yueying ^c   Burkhalter, Rebecca J ^c   Marga, Francoise ^c   Forgacs, Gabor ^c   Hudson, Laurie G ^d   Stack, M Sharon ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c University of Missouri   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e Medical Sciences Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTININ; CADHERIN; MATRIX METALLOPROTEINASE 14; NERVE CELL ADHESION MOLECULE; UVOMORULIN;

ASCITES TUMOR CELL; CARCINOGENESIS; CELL ADHESION; CELL AGGREGATION; CELL FUNCTION; CELL SURVIVAL; HUMAN; MICROENVIRONMENT; OVARY CANCER; OVARY METASTASIS; PERITONEUM; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR GROWTH;

ASCITES; CADHERINS; CARCINOMA; CELL ADHESION; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; HUMANS; INFLAMMATION; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOPHOSPHOLIPIDS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEPTIDE HYDROLASES; PERITONEAL NEOPLASMS; PHENOTYPE;

EID: 66949141951     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-98094-2_15     Document Type: Review

References (85)

1. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26:995-1005.
2. Wong AST, Auersperg N. Normal ovarian surface epithelium. Cancer Treat Res. 2002;107:161-183.
3. Darai E, Scoazec JY, Walker-Combrouze F, et al. Expression of cadherins in benign, borderline and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol. 1997;28:922-928.
4. Alper O, DeSantis ML, Stromberg K, et al. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer. 2000;88:566-574.
5. Auersperg N, Maines-Bandiera S, Dyck HG, et al. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest. 1994;71:510-518.
6. Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med. 2007;9:1-12.
7. Shih EM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
8. ACS Cancer Facts & Figures. Available at: www.cancer.org.
9. Hoskins WJ. Prospective on ovarian cancer; why prevent? J Cell Biochem Suppl. 1995;23:189-199.
10. Ghosh S, Wu Y, Stack MS. Ovarian cancer-associated proteinases. Cancer Treat Res. 2002;107:331-354.
11. Burleson KM, Hansen LK, Skubitz APN. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 2004;21:685-697.
12. Burleson KM, Casey RC, Skubitz KM, et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 2004;93:170-181.
13. Burleson KM, Boente MP, Pambuccian SE, et al. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 2006;4:1-16.
14. Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis. 2008;25:L643-L655.
15. Kenny HA, Krausz T, Yamada SD, et al. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007;121:1463-1472.
16. Offner FA, Obrist P, Stadlmann S, et al. IL6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine. 1995;7:542-547.
17. Mustea A, Pirvulescu C, Konsgen D, et al. Decreased IL1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine. 2008;42:77-84.
18. Freedman RS, Deavers M, Liu J, et al. Peritoneal inflammation - a microenvironment for epithelial ovarian cancer. J Transl Med. 2004;2:23-33.
19. Papadaki L, Beilby JOW. The fine structure of the surface epithelium of the human ovary. J Cell Sci. 1971;8:445-465.
20. Czernobilsky B, Moll R, Levy M, et al. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol. 1985;37:175-190.
21. Kruk PA, Uitto VJ, Firth JD, et al. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp Cell Res. 1994;215:97-108.
22. Carreiras F, Denoux Y, Staedel C, et al. Expression and localization of alphav integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol. 1996;62:260-267.
23. Skubitz AP, Bast RC, Wayner EA, et al. Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol. 1996;148:1445-1461.
24. Bridges JE, Englefield P, Boyd IE, et al. Expression of integrin adhesion molecules in normal ovary and epithelial ovarian tumors. Int J Gynecol Cancer. 1995;5:187-192.
25. Shield K, Riley C, Quinn MA, et al. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007;14:6-11.
26. Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha5 integrin, which is a therapeutic target. Cancer Res. 2008;68:2329-2339.
27. Moser TL, Pizzo SV, Bafetti LM, et al. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer. 1996;67:695-701.
28. Fishman DA, Kearns AM, Chilikuri K, et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by a2b1 integrin-mediated interaction with type I collagen. Invasion Metastasis. 1998;18:15-26.
29. Ellerbroek SM, Fishman DA, Kearns AS, et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 1999;59:1635-1641.
30. Barbolina MV, Adley BP, Ariztia EV, et al. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J Biol Chem. 2007;282:4924-4931.
31. Davidson B, Goldberg I, Reich R, et al. AlphaV and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol. 2003;90:248-257.
32. Davies BR,Worsley SD, PonderBA. Expression ofE-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and ovarian cancers. Histopathology. 1998;32:69-80.
33. Ho EY, Choi Y, Chae SW, et al. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int. 2006;56:62-70.
34. Voutilainen KA, Anttila MA, Sillanpaa SM, et al. Prognostic significance of E-cadherin- catenin complex in epithelial ovarian cancer. J Clin Pathol. 2006;59:460-467.
35. Forgacs G, Foty RA, Shafrir Y, et al. Viscoelastic properties of living embryonic tissues: a quantitative study. Biophys J. 1998;74:2227-2234.
36. Foty RA, Pfleger CM, Forgacs G, et al. Surface tensions of embryonic tissues predict their mutual envelopment behavior. Development. 1996;122:1611-1620.
37. Duguay D, Foty RA, Steinberg MS. Cadherin-mediated cell adhesion and tissue segregation: qualitative and quantitative determinants. Dev Biol. 2003;253:309-323.
38. diZerega GS, Rodgers KE. The Peritoneum. New York: Springer-Verlag; 1992.
39. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002;87:77-83.
40. Rahaman J, Cohen CJ. Impact of ascites on survival in advanced ovarian cancer. Proc Am Soc Clin Oncol. 2002;21:837.
41. Ayhan A, Gultekin M, Taskiran C, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer. 2006;17:68-75.
42. Gortzak-Uzan L, Ignatchenko A, Evangelou AI, et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatics analyses to identify putative biomarkers. J Proteome Res. 2008;7:339-351.
43. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1:1223-1232.
44. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719-723.
45. Fang X, Yu S, Bast RC, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004;279:9653-9661.
46. Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023-5032.
47. Reddy P, Liu L, Ren C, et al. Formation of E-cadherin mediated cell-cell adhesion activates AKT and MAPK via PI3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol. 2005;19:2564-2578.
48. Hudson LG, Zeineldin R, Silberberg M, et al. Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res. 2009;149.
49. Lafky JM, Wilken JA, Baron AT, et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785:232-265.
50. Said N, Socha MJ, Olearczyk JJ, et al. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res. 2007;5:1015-1030.
51. Santala M, Risteli J, Risteli L, et al. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer. Br J Cancer. 1998;77:1825-1831.
52. Abdel Axia MT, Abdel Aziz Wassef M, Kamel M, et al. Clinical evaluation of serum aminoterminal propeptide of type III procollagen as tumor marker in gynecologic malignancies. Tumori. 1993;79:219-223.
53. Zhu GG, Risteli J, Puistola U, et al. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res. 1993;53:5028-5032.
54. Mills GB, Eder A, Fang X, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Res Treat. 2002;107:259-284.
55. Do TV, Symowicz JC, Berman DM, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res. 2007;5:121-131.
56. Symowicz J, Adley BP, Woo MM, et al. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 2005;65:2234-2242.
57. Fishman DA, Liu, Y, Ellerbroek SM, et al. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001;61:3194-3199.
58. Graves LE, Ariztia EV, Navari JR, et al. Proinvasive properties of ovarian cancer ascitesderived membrane vesicles. Cancer Res. 2004;64:7045-7049.
59. Lee Z, Swaby RF, Liang Y, et al. Lysophosphatidic acid is a major regulator of growthregulated oncogene alpha in ovarian cancer. Cancer Res. 2006;66:2740-2748.
60. Said NA, Najwer I, Socha MJ, et al. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia. 2007;9:23-35.
61. Robinson-Smith TM, Isaacsohn I, Mercer CA, et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67: 5708-5716.
62. Hageman T, Robinson SC, Thompson RG, et al. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007;6:1993-2002.
63. Kassis J, Lkominek J, Kohn EC. Tumor microenvironment: what can effusions teach us? Diagn Cytopathol. 2004;33:316-319.
64. Greenaway J, Moorehead R, Shaw P, et al. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol. 2008;108:385-394.
65. Zietarska M, Maugard CM, Filali-Mouhim A, et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog. 2007;46:872-885.
66. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer initiating cells from primary human tumors. Cancer Res. 2008;68:4311-4320.
67. Hegedus B, Marga F, Jakab K, et al. The interplay of cell-cell and cell-matrix interactions in the invasive properties of brain tumors. Biophys J. 2006;91:2708-2720.
68. Battifora H, McCaughey WTE. Tumors of the serosal membranes. In: Atlas of Tumor Pathology, Third Series, Fascicle 15. Washington, DC: Armed Forces Institute of Pathology; 1994:1-117.
69. Zhang XY, Pettengell R, Nasiri N, et al. Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. J Soc Gynecol Investig. 1999;6:333-340.
70. Wang E, Ngalame Y, Panelli MC, et al. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res. 11:113-122.
71. Cannistra SA, Kansas GS, Niloff J. et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993;53:3830-3838.
72. Ahmed N, Riley C, Rice G, et al. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 2005;22:391-402.
73. Niedbala MJ, Crickard K, Bernacki RJ. In vitro degradation of extracellular matrix by human ovarian carcinoma cells. Clin Exp Metastasis. 1987;5:181-197.
74. Sawada M, Shii J, Akedo H, et al. An experimental model for ovarian tumor invasion of cultured mesothelial cell monolayer. Lab Invest. 1994;70:333-338.
75. Harvey W, Amlot, P. Colalgen production by human mesothelial cells in vitro. J Pathol. 1983;139:337-347.
76. Stylianou E, Jenner LA, Davies M, et al. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int. 1990;37:1563-1570.
77. Ellerbroek SM, Wu YI, Overall CM, et al. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem. 2001;276:24833-24842.
78. Hotary KB, Allen ED, Brooks PC, et al. Membrane type 1 matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 2003;114:33-45.
79. Symowicz J, Adley BP, Gleason KJ, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 2007;67:2030-2039.
80. Barbolina M, Adley, BP, Kelly, et al. Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest. 2008;88:602-614.
81. Barbolina MV, Adley BP, Shea LD, et al. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer. 2008;112:1632-1641.
82. BarbolinaMV, Adley BP, Kelly DL, et al. Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int J Cancer. 2009 (in press).
83. Langer S, Singer CF, Hudelist G, et al. Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol. 2006;27:345-352.
84. Zhai Y, Hotary KB, Nan B, et al. Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res. 2005;65:6543-6550.
85. Schaller G, Fuchs I, Ebert A, et al. The clinical importance of keratin 18 in breast cancer. Zentralbl Gynakol. 1999;121:126-130.